Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Get Rating)'s share price shot up 5.1% during trading on Thursday . The company traded as high as $11.63 and last traded at $11.63. 59,817 shares changed hands during trading, a decline of 97% from the average session volume of 2,000,791 shares. The stock had previously closed at $11.07.
Wall Street Analyst Weigh In
A number of analysts recently weighed in on the stock. Truist Financial cut their target price on shares of Iovance Biotherapeutics to $18.00 in a research note on Tuesday, August 23rd. The Goldman Sachs Group lowered their target price on shares of Iovance Biotherapeutics from $64.00 to $18.00 and set a "buy" rating for the company in a research note on Friday, July 1st. Chardan Capital lowered their price objective on Iovance Biotherapeutics from $31.00 to $30.00 in a research report on Friday, August 5th. Piper Sandler cut their target price on Iovance Biotherapeutics from $20.00 to $13.00 and set a "neutral" rating on the stock in a research report on Friday, May 27th. Finally, Robert W. Baird lowered their price target on Iovance Biotherapeutics from $34.00 to $25.00 and set an "outperform" rating for the company in a report on Friday, August 5th. One analyst has rated the stock with a sell rating, two have issued a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $23.80.
Get Iovance Biotherapeutics alerts:Iovance Biotherapeutics Stock Up 6.3 %
The business's fifty day moving average price is $11.83 and its 200 day moving average price is $12.90.
Iovance Biotherapeutics (NASDAQ:IOVA – Get Rating) last posted its quarterly earnings data on Thursday, August 4th. The biotechnology company reported ($0.63) earnings per share for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.03). During the same period in the prior year, the business earned ($0.53) earnings per share. As a group, sell-side analysts anticipate that Iovance Biotherapeutics, Inc. will post -2.53 EPS for the current fiscal year.Institutional Trading of Iovance Biotherapeutics
Several hedge funds have recently made changes to their positions in IOVA. Herold Advisors Inc. acquired a new stake in Iovance Biotherapeutics in the first quarter valued at about $33,000. Spire Wealth Management purchased a new stake in shares of Iovance Biotherapeutics in the first quarter valued at approximately $47,000. Lazard Asset Management LLC grew its holdings in Iovance Biotherapeutics by 38.5% during the first quarter. Lazard Asset Management LLC now owns 3,357 shares of the biotechnology company's stock worth $55,000 after acquiring an additional 934 shares during the period. Retirement Group LLC raised its position in Iovance Biotherapeutics by 85.1% in the first quarter. Retirement Group LLC now owns 4,350 shares of the biotechnology company's stock worth $72,000 after acquiring an additional 2,000 shares in the last quarter. Finally, MetLife Investment Management LLC acquired a new stake in Iovance Biotherapeutics in the first quarter valued at $83,000.
About Iovance Biotherapeutics
(Get Rating)
Iovance Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma.
Read More
- Get a free copy of the StockNews.com research report on Iovance Biotherapeutics (IOVA)
- Why Medical Products Maker Repligen May Be A Potential Buy
- At 10%, Is Arbor Realty Trust Dividend Worth It?
- Investors Should Tune Into RF Industries
- 2 Reasons Netflix Might Have Just Bottomed Out
- Murphy USA Outperforming Other Mid-caps, But Is It A Buy Now?
Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.